[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Nanfang Hospital, Southern Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":602},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,138,0,25,[9,40,62,91,118,144,169,189,213,235,260,279,303,326,354,376,395,425,449,472,499,517,534,555,578],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100053813","prevention-of-epstein-barr-virus-reactivation-with-the-atg-based-haploidentical-protocol-combined-with-rituximab-in-children-undergoing-allogeneic-hematopoietic-stem-cell-transplantation-100053813",false,"NCT07693881","Prevention of Epstein-Barr Virus Reactivation With the ATG-based Haploidentical Protocol Combined With Rituximab in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation","Prevention of Epstein-Barr Virus Reactivation With the ATG-based Haploidentical Protocol Combined With Rituximab in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* ECOG performance status score of 0-1, or Karnofsky Performance Status (KPS) score \\> 80.\n* Diagnosis of a disease that has an indication for allogeneic hematopoietic stem cell transplantation.\n* Donor source is a related HLA haploidentical (half-matched) family donor.\n* Use of an \"ATG-based\" transplantation conditioning\u002Fprotocol.\n* Written informed consent obtained from the patient's legal guardian prior to enrollment in this study.\n\nExclusion Criteria:\n\n* Lansky performance score \\\u003C 60.\n* Diagnosis of EBV-associated hemophagocytic lymphohistiocytosis (HLH) or chronic active EBV infection.\n* Serum EBV DNA level \\> 100 U\u002FmL before transplantation.\n* Use of B-cell depleting immunotherapy (e.g., rituximab, blinatumomab, etc.) within 2 weeks prior to preconditioning.\n* Known allergy or hypersensitivity to rituximab.\n* Severe organ dysfunction\n* The subject or their legal guardian is unwilling or unable to comply with the protocol, or refuses to sign the informed consent document.\n* Patients deemed by the investigator to be unsuitable for participation in this trial.","ALL","18 Years",{"count":20,"type":21},106,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn if adding rituximab to the ATG-based Protocol can prevent Epstein-Barr virus (EBV) from reactivating in children who have received an allogeneic haploidentical hematopoietic stem cell transplant. It will also learn about the safety of adding rituximab. The main questions it aims to answer are:\n\nDoes giving rituximab twice during the conditioning regimen lower the number of children who have EBV reactivation after transplant?\n\nWhat medical problems or side effects do children experience when they receive rituximab in addition to the ATG-based Protocol?\n\nResearchers will compare the group that receives rituximab (two doses before transplant) with a control group that receives no rituximab, to see if the addition of rituximab effectively prevents EBV reactivation.\n\nParticipants will:\n\nReceive either rituximab (two doses during the preconditioning phase) or no extra treatment (control group), depending on which group they are assigned to\n\nHave regular follow-up visits for blood tests to monitor their EBV-DNA levels\n\nKeep a record of any symptoms or health changes they notice between visits",[27],"EBV Infection After Allogenic HSCT","NOT_YET_RECRUITING","2026-07-10",{"date":31,"type":32},"2026-07-13","ACTUAL",{"date":34,"type":21},"2026-07-01",{"date":36,"type":21},"2029-12-31",{"name":38,"class":39},"Nanfang Hospital, Southern Medical University","OTHER",{"id":41,"slug":42,"hasResults":12,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":12,"sex":17,"minAge":47,"maxAge":18,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":50,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":4},"100644839","rituximab-combining-with-low-dose-mycophenolate-mofetil-on-proliferative-lupus-nephritis-in-children-100644839","NCT07675291","Rituximab Combining With Low-Dose Mycophenolate Mofetil on Proliferative Lupus Nephritis in Children","Efficacy and Safety of Rituximab Combining With Low-Dose Mycophenolate Mofetil in the Induction Therapy of Proliferative Lupus Nephritis in Children","Inclusion Criteria:\n\n1. Children aged 3-18 years old, regardless of sex;\n2. SLE patients who meet the 2019 EULAR\u002FACR SLE criteria or the 2012 SLICC diagnostic criteria;\n3. Diagnosed as lupus nephritis and the classification was consistent with proliferative lupus nephritis (type III or IV, with or without type V);\n4. White blood cell count ≥3.0×10\\^9\u002FL, and lymphocyte count ≥ 0.5× 10\\^9\u002FL and CD20 (or CD19)≥1\u002Ful;\n5. No cyclophosphamide or rituximab induction therapy was used before enrollment;\n6. Informed consent form is signed by the guardian and children over 8 years old;\n7. In the active stage of the disease, the 24-hour urine protein quantification ≥25mg\u002Fkg, or the urine protein\u002Fcreatinine ≥1.0mg\u002Fmg;\n8. Estimated GFR≥60ml\u002Fmin\u002F1.73m\\^2 (improved Swchartz formula).\n\nExclusion Criteria:\n\n1. Patients with lupus encephalopathy;\n2. Estimated GFR\\\u003C60ml\u002Fmin\u002F1.73m\\^2(Swchartz formula);\n3. HBV-antigen positive, HCV or HIV antibody positive;\n4. Severe infection (including chronic hepatitis, EB virus or cytomegalovirus infection) and tuberculosis;\n5. Allergic to the active ingredients or any auxiliary materials in rituximab, mycophenolate mofetil or cyclophosphamide;\n6. Severe heart failure and liver function damage;\n7. Patients who is not suitable to participate in this study judged by the researchers.","3 Years",{"count":49,"type":21},112,[24],"The objective of this study is to assess the efficacy and safety of rituximab combining with low-dose mycophenolate mofetil in the induction therapy of proliferative lupus nephritis in children.",[53],"Lupus Nephritis","2026-06-29",{"date":56,"type":32},"2026-06-30",{"date":58,"type":21},"2026-06",{"date":60,"type":21},"2028-12-31",{"name":38,"class":39},{"id":63,"slug":64,"hasResults":12,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":4,"eligibilityCriteria":68,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":69,"targetDuration":4,"studyType":22,"phases":71,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},"100517465","doxepin-solution-for-alleviation-of-stubborn-breakthrough-pain-induced-by-swallowing-in-patients-receiving-radiotherapy-for-nasopharyngeal-carcinoma-100517465","NCT06017895","Doxepin Solution for Alleviation of Stubborn Breakthrough Pain Induced by Swallowing in Patients Receiving Radiotherapy for Nasopharyngeal Carcinoma","Doxepin Solution for Alleviation of Stubborn Breakthrough Pain Induced by Swallowing in Patient Receiving Radiotherapy for Nasopharyngeal Carcinoma: A Multicenter, Randomized, Controlled, Double-Blind Clinical Trial","Inclusion Criteria:\n\n1. Provide informed written consent.\n2. Age ≥ 18 years.\n3. Histologically confirmed as nasopharyngeal carcinoma, and currently undergoing radical radiotherapy or chemoradiotherapy.\n4. Physical examination demonstrating the presence of radiation-induced mucositis in the oral cavity and\u002For oropharynx.\n5. At least 4 (out of 10) patient-reported swallowing-induced pain as measured by the numeric rating scale of pain.\n6. Being able to complete the questionnaires independently or with assistance.\n7. ECOG Performance Status 0, 1 or 2.\n\nExclusion Criteria:\n\n1. Known allergy to doxepin, tricyclic antidepressants, or any known component of the drug formulation.\n2. Use of a tricyclic antidepressant or monoamine oxidase inhibitor within 14 days prior to registration.\n3. Current untreated or unhealed oral candidiasis or oral herpes simplex virus infection.\n4. Untreated narrow angle glaucoma within 6 weeks prior to registration.\n5. Untreated urinary retention within 6 weeks prior to registration.\n6. Administration of cryotherapy to prevent oral mucositis within 6 weeks prior to registration.\n7. Current serious heart disease or a recent history of myocardial infarction.\n8. Current untreated or unresolved conditions like epilepsy, hyperthyroidism, hepatic dysfunction, delirium, and neutropenia.\n9. Pregnant or lactating women.",{"count":70,"type":21},178,[24],"The goal of this clinical trial is to explore the effectiveness and adverse reactions of doxepin solution spray for alleviation of stubborn breakthrough pain induced by swallowing in patients receiving radiotherapy for nasopharyngeal carcinoma.",[74],"Swallowing-induced Pain",[76,77,78,79,80],"Nasopharyngeal carcinoma","Oral mucositis","Radiotherapy","Swallowing-induced pain","Doxepin","RECRUITING","2026-06-22",{"date":84,"type":32},"2026-06-23",{"date":86,"type":32},"2023-10-31",{"date":88,"type":21},"2026-08-31",{"name":38,"class":39},1,{"id":92,"slug":93,"hasResults":12,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":98,"enrollmentInfo":99,"targetDuration":4,"studyType":22,"phases":101,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":90},"100643343","phase-2-luspatercept-vs-epoetin-in-treating-poor-erythroid-engraftment-for-hematological-malignancies-100643343","NCT07636486","Luspatercept vs Epoetin in Treating Poor Erythroid Engraftment for Hematological Malignancies","Luspatercept Versus Epoetin in Treating Poor Erythroid Engraftment for Hematological Malignancies","Inclusion Criteria:\n\n* 18-65 years\n* Hematologic malignancies\n* Poor erythroid engraftment after the first allo-HSCT\n* Complete remission post-transplantation\n* Eastern Cooperative Oncology Group performance status of 0-2\n* Epoetin-naive\n* Endogenous serum erythropoietin concentration \\\u003C500 U\u002FL\n\nExclusion Criteria:\n\n* Life expectancy shorter than 30 days post-transplantation\n* Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure)\n* Patients with any conditions not suitable for the trial (investigators' decision)","65 Years",{"count":100,"type":21},90,[102,103],"PHASE2","PHASE3","Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective therapy for hematological malignancies. Nonetheless, poor graft function remains a life-threatening complication after allo-HSCT. Poor erythroid engraftment is associated with increased bleeding events and shorter survival. Current treatment methods such as epoetin or repeated red-cell transfusions are not effective for poor erythroid engraftment, with limited and transient responses. Retrospective studies suggested that luspatercept showed efficacy in patients with anemia post-transplantation or poor erythroid engraftment. However, there are no studies comparing luspatercept versus epoetin for the treatment of poor erythroid engraftment. Therefore, we conducted a randomized controlled study to compared the effect of luspatercept versus epoetin in treating poor erythroid engraftment for hematological malignancies.",[106,107,108,109],"Luspatercept","Epoetin","Poor Erythroid Engraftment","Hematological Malignancies","2026-06-04",{"date":112,"type":32},"2026-06-09",{"date":114,"type":21},"2026-06-15",{"date":116,"type":21},"2030-12-31",{"name":38,"class":39},{"id":119,"slug":120,"hasResults":12,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":22,"phases":127,"briefSummary":128,"conditions":129,"keywords":133,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":138,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":90},"100643728","phase-2-egfr-tkis-plus-pd-1-in-egfr-mutant-advanced-nsclc-100643728","NCT07637448","EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLC","A Clinical Study Evaluating the Preliminary Antitumor Activity and Safety of EGFR-TKIs Combined With PD-1 Monoclonal Antibody as First-Line Therapy in Patients With EGFR-Mutant Advanced Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n1. Patients with histologically or cytologically confirmed, previously untreated EGFR-mutant (19del\u002FL858R) locally advanced or metastatic (stage IIIB\u002FIIIC or IV) non-small cell lung cancer (NSCLC), according to the 9th edition of the TNM staging system for lung cancer jointly issued by the International Association for the Study of Lung Cancer (IASLC) and the American Joint Committee on Cancer (AJCC);\n2. Male or female patients aged ≥ 18 years;\n3. Patients who are willing to receive third-generation EGFR-TKI targeted therapy, followed by maintenance therapy with a PD-1 antibody during the stable phase of the disease (defined as no further tumor shrinkage for at least two consecutive assessments based on RECIST v1.1 criteria);\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;\n5. At least one measurable or non-measurable but evaluable lesion according to RECIST version 1.1;\n6. Adequate organ function;\n7. Female or male patients of childbearing potential must agree to use highly effective contraceptive measures throughout the study period;\n8. Willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other study requirements as specified in the visit schedule.\n\nExclusion Criteria:\n\n1. Patients who are ineligible for standard anti-tumor therapy according to routine clinical practice;\n2. Prior treatment with anti-PD-1\u002FPD-L1 immunotherapy;\n3. Concurrent enrollment in another clinical study;\n4. Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;\n5. Receipt of systemic corticosteroids or other immunosuppressive therapy within 2 weeks prior to the first dose of study drug;\n6. Receipt of any live vaccine within 4 weeks prior to the first dose of study drug, or planned receipt of live vaccine during the study period;\n7. Presence of brainstem, leptomeningeal, spinal cord metastasis, or spinal cord compression;\n8. Presence of uncontrolled concomitant diseases, including but not limited to decompensated cirrhosis, nephrotic syndrome, uncontrolled metabolic disorders, etc.;\n9. History of severe gastrointestinal ulcer, gastrointestinal perforation, fistula or obstruction, intra-abdominal abscess, or acute gastrointestinal bleeding within 6 months prior to the first dose, or other gastrointestinal diseases that, in the investigator's opinion, may predispose to bleeding or perforation;\n10. Presence of severe uncontrolled cardiovascular disease;\n11. Interstitial lung disease (ILD) (including pulmonary fibrosis or radiation pneumonitis) requiring corticosteroid therapy, or current ILD\u002Fnon-infectious pneumonitis;\n12. Concomitant pulmonary disease resulting in clinically severe impairment of respiratory function;\n13. Chronic autoimmune disease or inflammatory disease requiring systemic therapy or receiving systemic therapy within 2 years prior to the first dose;\n14. Active or history of documented inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis, or chronic diarrhea), intestinal obstruction, or extensive bowel resection;\n15. Diagnosis of Gilbert's syndrome;\n16. Severe infection within 4 weeks prior to the first dose, including but not limited to complications requiring hospitalization, sepsis, or severe pneumonia;\n17. Known active pulmonary tuberculosis;\n18. Known active syphilis infection;\n19. Known history of immunodeficiency, or positive test for human immunodeficiency virus (HIV) antibody;\n20. Presence of active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection;\n21. Known allergy to any component of any study drug, history of severe allergic reactions (e.g., anaphylactic shock), history of severe hypersensitivity to other monoclonal antibodies or recombinant protein-based substances, or history of severe infusion reactions;\n22. Women who are pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study period;\n23. Any disease, medical condition, organ system dysfunction, or social circumstance (including but not limited to psychiatric illness, substance\u002Falcohol abuse, history of drug abuse, etc.) that, in the investigator's opinion, may interfere with the subject's ability to provide informed consent, adversely affect the subject's cooperation and participation in the study, or confound the interpretation of study results.",{"count":126,"type":21},32,[102],"This study is an open-label, multicenter, single-arm clinical study.",[130,131,132],"Lung Cancer Non-Small Cell Cancer (NSCLC)","EGFR Activating Mutation","PD-1 Antibody",[134,135,136,137],"Non-Small Cell Cancer (NSCLC)","EGFR-Mutant","EGFR-TKIs","PD-1 Monoclonal Antibody",{"date":112,"type":32},{"date":140,"type":32},"2026-05-21",{"date":142,"type":21},"2030-03-01",{"name":38,"class":39},{"id":145,"slug":146,"hasResults":12,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":152,"enrollmentInfo":153,"targetDuration":4,"studyType":22,"phases":154,"briefSummary":155,"conditions":156,"keywords":158,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":90},"100640679","efficacy-and-safety-of-anlotinib-combined-with-bemocizumab-for-neoadjuvant-therapy-of-esophageal-squamous-cell-carcinomaescc-100640679","NCT07627347","Efficacy and Safety of Anlotinib Combined With Bemocizumab for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma(ESCC)","Clinical Trial on the Efficacy and Safety of Anlotinib Combined With Bemocizumab for Neoadjuvant Therapy of Resectable Esophageal Squamous Cell Carcinoma","RAOS","Inclusion Criteria:\n\n1. Aged 18-70, both male and female\n2. After gastroscopy\u002Fultrasonic gastroscopy biopsy, the pathology suggests squamous cell carcinoma of the esophagus, and the clinical diagnosis is cT2N1-2M0 or cT3N0-2M0, with TNM staging of II-III B\n3. Patients with non-cervical esophageal cance\n4. The patient has not previously received systemic or local treatment for esophageal cancer, and according to the RECIST 1.1 criteria, there is at least one measurable lesion for imaging evaluation of neoadjuvant therapy\n5. ECOG PS: 0-1\n6. Expected survival duration ≥ 12 months\n7. The subjects had no functional disorders of major organs, and the researchers assessed that thyroid, lung, liver, kidney, and heart functions were basically normal;\n8. Women of childbearing age must have already taken reliable contraceptive measures or undergone a pregnancy test (serum or urine) within 7 days prior to enrollment, with a negative result, and be willing to use appropriate contraception during the trial and for 8 weeks after the last administration of the trial medication. For males, they must agree to use appropriate contraception during the trial and for 8 weeks after the last administration of the trial medication, or have undergone surgical sterilization\n9. The subjects voluntarily joined this study, signed the informed consent form, exhibited good compliance, actively cooperated with the planned schedule by returning to the hospital for regular clinical follow-ups and necessary treatments, and cooperated with the regular collection of blood and tissue samples\n\nExclusion Criteria:\n\n1. Within the past 5 years, there has been or is currently a co-occurrence of other malignant tumors, except for cured cervical carcinoma in situ, non-melanoma skin cancer, and superficial bladder tumors \\[Ta (non-invasive tumor), Tis (carcinoma in situ), and T1 (tumor invades the basement membrane)\\]\n2. Patients with ulcerative esophageal squamous cell carcinoma\n3. Patients with esophageal fistula or tracheal fistula;\n4. Those who are allergic to anlotinib and bemusuban\n5. Those with a history of immune deficiency, including HIV-positive or suffering from other acquired or congenital immune deficiency diseases, or those who have undergone organ transplantation\n6. Patients with any severe and\u002For uncontrolled diseases\n7. Unresolved toxic reactions above CTC AE Grade 1 caused by any previous treatment, excluding alopecia;\n8. Individuals with multiple factors affecting oral medication administration, such as inability to swallow, chronic diarrhea, and intestinal obstruction\n9. Urine routine test indicates proteinuria ≥++ and confirmed 24-hour urine protein quantitation \\> 1.0 g\n10. Subjects who underwent major surgical procedures, incisional biopsies, or significant traumatic injuries within 28 days prior to grouping\n11. Abnormal coagulation function: INR \\> 1.5 or prothrombin time (PT) \\> ULN + 4 seconds or APTT \\> 1.5ULN), with a tendency to bleed or undergoing thrombolytic or anticoagulant therapy; patients who have experienced any bleeding or hemorrhagic events ≥ CTCAE Grade 3 within 4 weeks before grouping, have unhealed wounds, ulcers, or fractures\n12. Those who have experienced arterial or venous thromboembolic events within 6 months, such as cerebrovascular accidents (including transient ischemic attacks), deep vein thrombosis, and pulmonary embolism\n13. Pregnant or lactating women\n14. Patients with distant metastasis\n15. Patients with significant bone marrow suppression\n16. Suffering from mental illness or having a history of abuse of psychotropic drugs;\n17. Patients who have participated in other drug clinical trials within 4 weeks;\n18. Patients with concomitant diseases that, according to the researcher's judgment, pose serious risks to patient safety or affect patients' ability to complete the study\n19. Individuals with hereditary bleeding tendency, coagulation dysfunction, potential invasion of large blood vessels, and other bleeding risks, who have experienced clinically significant bleeding symptoms or have a clear tendency to bleed within the previous 3 months before enrollment, such as gastrointestinal bleeding, bleeding gastric ulcer, and baseline fecal occult blood test result of ++ or above\n20. Researchers consider those who are not suitable for inclusion","70 Years",{"count":7,"type":21},[24],"This study aims to explore the efficacy and safety of anlotinib combined with bemocizumab as neoadjuvant therapy for resectable esophageal squamous cell carcinoma, with the goal of improving the pathological complete response (pCR) rate and margin-negative resection(R0) resection rate in patients undergoing esophageal cancer surgery, as well as enhancing disease-free survival (DFS) in postoperative patients. This will provide guidance and new options for the treatment of patients with locally advanced esophageal cancer.",[157],"ESCC",[157,159,160,161],"Neoadjuvant therapy Immunotherapy","Chemotherapy-free","Anlotinib","2026-05-31",{"date":110,"type":32},{"date":165,"type":32},"2026-05-18",{"date":167,"type":21},"2028-12-30",{"name":38,"class":39},{"id":170,"slug":171,"hasResults":12,"nctId":172,"briefTitle":173,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":175,"targetDuration":4,"studyType":177,"phases":4,"briefSummary":178,"conditions":179,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":90},"100639720","correlation-analysis-of-gene-characteristics-of-malignant-tumors-with-prognosis-100639720","NCT07622667","Correlation Analysis of Gene Characteristics of Malignant Tumors With Prognosis","Inclusion Criteria:\n\n1. Voluntarily sign the informed consent form.\n2. Treated at Nanfang Hospital, Southern Medical University between January 2017 and December 2025.\n3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2.\n4. Availability of surplus routinely discarded clinical tumor tissue samples (biopsy specimens or pathological sections) or blood samples for assays such as sequencing, staining, ELISA, drug sensitivity testing, and flow cytometry.\n\nExclusion Criteria:Patients deemed by the investigator to be unsuitable for participation in this study.",{"count":176,"type":21},500,"OBSERVATIONAL","This study is a single-center observational investigation aimed at systematically exploring the key molecular features influencing the prognosis of malignant tumors by integrating multidimensional clinical information with multi-omics molecular data. The goal is to provide a critical scientific basis for constructing precise prognostic prediction models, identifying potential therapeutic targets, and optimizing clinical treatment strategies. The study plans to consecutively enroll adult patients with histologically confirmed malignant tumors who received antitumor therapy at our hospital between January 2017 and December 2025. Clinical data (including demographic characteristics, tumor pathology information, treatment histories, and survival follow-up data) will be systematically collected from electronic medical records. Additionally, tumor tissue or blood samples will be obtained from the patients for sequencing, staining, ELISA, drug sensitivity testing, and flow cytometry analysis to comprehensively characterize the genomic features, immune microenvironment, and cellular heterogeneity of the tumors.",[180],"Malignant Tumors","2026-05-28",{"date":183,"type":32},"2026-06-03",{"date":185,"type":21},"2026-05-29",{"date":187,"type":21},"2027-06-30",{"name":38,"class":39},{"id":190,"slug":191,"hasResults":12,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":196,"sex":17,"minAge":18,"maxAge":197,"enrollmentInfo":198,"targetDuration":4,"studyType":22,"phases":200,"briefSummary":201,"conditions":202,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":210,"leadSponsor":212,"locationsCount":90},"100637810","electrolyte-beverage-combined-with-polyethylene-glycol-for-colonoscopy-bowel-preparation-100637810","NCT07608120","Electrolyte Beverage Combined With Polyethylene Glycol for Colonoscopy Bowel Preparation","Randomized Controlled Trial of Different Ratios of Electrolyte Beverage and Water Combined With Polyethylene Glycol on Bowel Preparation Quality and Ingestion Rhythm Before Colonoscopy","Inclusion Criteria:\n\n* Adults aged 18-75 years scheduled to undergo elective colonoscopy\n* Meet the standard clinical indications for colonoscopy;\n* Able to understand and comply with the bowel preparation procedure and complete oral polyethylene glycol (PEG) intake as required;\n* Able to comply with study-related data collection and follow-up;\n* Provide written informed consent voluntarily.\n\nExclusion Criteria:\n\n* Previously diagnosed colorectal cancer, intestinal obstruction, or suspected intestinal obstruction;\n* Active gastrointestinal bleeding or a definite history of gastrointestinal bleeding within the past 4 weeks (including melena, hematochezia, or hematemesis);\n* Severe renal insufficiency, decompensated heart failure, significant electrolyte imbalance, or other conditions unsuitable for PEG bowel preparation;\n* Known allergy to polyethylene glycol or components of the electrolyte beverage used in the study;\n* Pregnant or breastfeeding women;\n* Any other condition considered by the investigators to make the participant unsuitable for the study.",true,"75 Years",{"count":199,"type":21},405,[24],"This randomized controlled trial aims to evaluate the effects of different ratios of electrolyte beverage and water combined with polyethylene glycol (PEG) on bowel preparation quality before colonoscopy. Participants undergoing elective colonoscopy will be randomly assigned to one of three bowel preparation regimens: PEG prepared with water only, PEG prepared with a low ratio of electrolyte beverage and water, or PEG prepared with a medium ratio of electrolyte beverage and water. The primary outcome is adequate bowel preparation assessed by the Boston Bowel Preparation Scale (BBPS). Secondary outcomes include bowel preparation completion rate, tolerability, adverse events, repeat colonoscopy rate, adenoma detection rate, and ingestion rhythm characteristics during bowel preparation. This study also aims to explore whether electrolyte beverage-assisted bowel preparation may improve bowel cleansing quality by influencing participants' ingestion rhythm and adherence during PEG intake.",[203,204,205],"Colonoscopy","Bowel Preparation Solutions","Colorectal Cancer Screening","2026-05-24",{"date":208,"type":32},"2026-05-27",{"date":165,"type":32},{"date":211,"type":21},"2027-05-31",{"name":38,"class":39},{"id":214,"slug":215,"hasResults":12,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":4,"eligibilityCriteria":219,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":220,"targetDuration":4,"studyType":177,"phases":4,"briefSummary":222,"conditions":223,"keywords":225,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":232,"leadSponsor":234,"locationsCount":90},"100641088","efficacy-and-safety-of-indobufen-aspirin-cilostazol-and-clopidogrel-in-the-treatment-of-ischemic-stroke-100641088","NCT07604298","Efficacy and Safety of Indobufen, Aspirin, Cilostazol and Clopidogrel in the Treatment of Ischemic Stroke","Efficacy and Safety of Indobufen, Aspirin, Cilostazol, and Clopidogrel in the Treatment of Ischemic Stroke: a Single-center, Retrospective Study","Inclusion Criteria:\n\n1. Age ≥ 18 years;\n2. Diagnosed with acute ischemic stroke (AIS) patients according to the Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2018 ;\n3. Hospitalized in the Department of Neurology, Nanfang Hospital, Southern Medical University, between January 2020 and December 2025;\n4. Received one of the following as a secondary prevention regimen within 7 days after discharge: indobufen, aspirin, clopidogrel, or cilostazol, either as monotherapy or as dual therapy;\n5. Have follow-up records at 1 year after treatment initiation.\n\nExclusion Criteria:\n\n1. Already having long-term anticoagulant therapy at baseline;\n2. History of hemorrhagic stroke or active bleeding;\n3. Severe hepatic or renal dysfunction (defined as AST\u002FALT \\> 3 times the upper limit of normal, or estimated glomerular filtration rate \\\u003C 30 mL\u002Fmin\u002F1.73m²), end-stage disease, intracranial tumor, or intracranial infection.",{"count":221,"type":21},2000,"Through a single-center retrospective cohort study of acute ischemic stroke (AIS) patients receiving secondary prevention with indobufen, clopidogrel, cilostazol, or aspirin as monotherapy or dual therapy, we aim to compare the real-world effectiveness and safety of these four antiplatelet regimens. Through closely tracking the recurrence of stroke (including ischemic and hemorrhagic stroke) and bleeding events (GUSTO-defined) within one year of treatment, we evaluate the association between each antiplatelet agent and the risk of stroke recurrence, thereby providing critical evidence to guide individualized antiplatelet therapy in AIS patients.",[224],"Acute Ischemic Stroke",[226,227,228],"Stroke recurrence","Antiplatelet therapy","Secondary prevention",{"date":230,"type":32},"2026-05-22",{"date":34,"type":21},{"date":233,"type":21},"2027-06-01",{"name":38,"class":39},{"id":236,"slug":237,"hasResults":12,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":4,"eligibilityCriteria":241,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":197,"enrollmentInfo":242,"targetDuration":4,"studyType":22,"phases":243,"briefSummary":244,"conditions":245,"keywords":248,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":255,"startDateStruct":256,"completionDateStruct":257,"leadSponsor":259,"locationsCount":90},"100639029","phase-2-adaptive-adjuvant-therapy-after-neoadjuvant-therapy-and-gastrectomy-for-gastric-or-gastroesophageal-junction-adenocarcinoma-100639029","NCT07603349","Adaptive Adjuvant Therapy After Neoadjuvant Therapy and Gastrectomy for Gastric or Gastroesophageal Junction Adenocarcinoma","Efficacy and Safety of Postoperative Adaptive Adjuvant Therapy After Neoadjuvant Therapy and Radical Gastrectomy for Gastric or Gastroesophageal Junction Adenocarcinoma: A Prospective, Multicenter, Open-Label Clinical Trial","Key Inclusion Criteria:\n\n1. Voluntarily signed written informed consent.\n2. Aged 18 to 75 years, inclusive, regardless of sex.\n3. Underwent radical gastrectomy with D2 or more extended lymphadenectomy and achieved R0 resection. Surgical approaches may include open or laparoscopic surgery.\n4. Histopathologically confirmed gastric or gastroesophageal junction adenocarcinoma.\n5. Received preoperative neoadjuvant immunotherapy combined with chemotherapy, including oxaliplatin plus fluoropyrimidine-based chemotherapy. Immunotherapy may include anti-PD-1 monoclonal antibodies, anti-PD-L1 monoclonal antibodies, PD-1\u002FCTLA-4 bispecific antibodies, and other immune checkpoint inhibitors.\n6. Eligible for one of the following predefined cohorts:\n\n   * Cohort 1: TRG grade 3 and postoperative pathological stage ypT3-4N2-3M0.\n   * Cohort 2: TRG grade 0 and postoperative pathological stage ypT0N0M0.\n7. ECOG performance status of 0 or 1.\n8. No evidence of metastasis or recurrence on postoperative imaging before enrollment.\n9. Adequate organ function, defined as hematologic, hepatic, renal, and thyroid function meeting the protocol-specified criteria based on laboratory tests performed within 14 days before randomization.\n10. Willing and able to comply with the study treatment, scheduled visits, laboratory tests, and other study procedures.\n11. Female participants of childbearing potential must have a negative pregnancy test before enrollment and agree to use effective contraception during the study and for 6 months after the last dose of study treatment. Male participants with female partners of childbearing potential must agree to use effective contraception during the study and for 6 months after the last dose of study treatment.\n\nKey Exclusion Criteria:\n\n1. Presence of liver, peritoneal, or other distant metastases.\n2. Inability to take oral medications.\n3. Unresolved postoperative complications at the time of randomization, such as postoperative infection, anastomotic leakage or wound dehiscence, gastrointestinal bleeding, pancreatic fistula, or intestinal obstruction.\n4. Uncontrolled pericardial effusion, uncontrolled pleural effusion, or clinically significant moderate or greater ascites at screening, defined as any of the following: pleural effusion or ascites with clinical symptoms and detectable by physical examination; or pleural effusion or ascites requiring drainage and\u002For intracavitary treatment during screening.\n5. Underwent any surgery requiring general anesthesia that was not related to gastric cancer within 28 days before randomization.\n6. History of or current diagnosis of another malignancy within 5 years.\n7. Active or prior autoimmune disease that may relapse or require immunosuppressive treatment within 2 weeks or during the study period; or a history of immunodeficiency, including HIV positivity or other acquired or congenital immunodeficiency disease; or a history of organ transplantation.\n8. Participation in another clinical study, or any condition that may interfere with the interpretation of the study results.\n9. Any other severe acute or chronic disease that, in the investigator's judgment, may increase the risk associated with study participation or study treatment.\n10. Active or uncontrolled infection requiring systemic antibiotic therapy within 2 weeks before randomization or at the time of randomization.\n11. Diagnosis of interstitial pneumonia, noninfectious pneumonitis, pulmonary fibrosis, or acute lung disease.\n12. Active tuberculosis within 1 year or previous anti-tuberculosis treatment.\n13. Female participants who are pregnant, breastfeeding, or planning to become pregnant during treatment or within 6 months after the end of treatment.\n14. History of psychotropic drug abuse with inability to discontinue, or presence of a psychiatric disorder.\n15. Patients considered unsuitable for participation in this study by the investigator.",{"count":199,"type":21},[102,103],"The goal of this clinical trial is to evaluate postoperative adaptive adjuvant therapy in patients with gastric or gastroesophageal junction adenocarcinoma after neoadjuvant chemotherapy plus immunotherapy and radical gastrectomy.The main questions it aims to answer are:\n\n1. In patients with poor pathological response, does switching to a alternative postoperative treatment regimen improve survival?\n2. In patients with complete pathological response, can observation without routine postoperative treatment maintain favorable survival outcomes? Participants will be assigned to different cohorts according to their pathological response after surgery and will be followed regularly for recurrence, survival, and treatment-related side effects.",[246,247],"Gastric Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma",[249,250,251,252,253,254],"Gastric cancer","Gastroesophageal junction cancer","Neoadjuvant therapy","Adaptive adjuvant therapy","Pathological response","Prognosis",{"date":230,"type":32},{"date":58,"type":21},{"date":258,"type":21},"2029-12",{"name":38,"class":39},{"id":261,"slug":262,"hasResults":12,"nctId":263,"briefTitle":264,"officialTitle":264,"acronym":265,"eligibilityCriteria":266,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":267,"targetDuration":4,"studyType":22,"phases":269,"briefSummary":271,"conditions":272,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":274,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":278,"locationsCount":4},"100637504","phase-4-efficacy-and-safety-of-nefecon-on-prevention-of-relapse-of-iga-nephropathy-a-randomized-double-blinded-placebo-controlled-trial-100637504","NCT07604311","Efficacy and Safety of Nefecon on Prevention of Relapse of IgA Nephropathy: a Randomized, Double-blinded, Placebo-Controlled Trial","NeFRIN","Inclusion Criteria:\n\n* Diagnosed primary IgAN with biopsy verification.\n* Female or male participants ≥18 years of age.\n* Completion of 9 months of Nefecon 16 mg QD at the Baseline visit.\n* Proteinuria ≥ 1g\u002Fd prior to initiation of Nefecon\n* Proteinuria\\\u003C0.5 g\u002Fday (or UPCR \\\u003C0.5 g\u002Fg) at screening\n* eGFR ≥30 ml\u002Fmin\u002F1.73m² at screening\n* On stable treatment with supportive treatment（including RAASi, SGLT2i, ERA） for at least 1 month prior to the Baseline visit\n\nExclusion Criteria:\n\n* Systemic diseases that may cause mesangial immunoglobulin A deposition, including but not limited to IgAVN, systemic lupus erythematosus, dermatitis herpetiformis, ankylosing spondylitis, and others;\n* Presence of other glomerulopathies (e.g., C3 glomerulopathy, nephrotic syndrome and\u002For diabetes nephropathy), active infection, severe hepatic impairment (Child-Pugh Class C), congestive heart failure, and a history of malignant tumor within the past 5 years.\n* On current or planned dialysis or kidney transplantation;\n* Participants who have been treated with systemic glucocorticoids and immunosuppressive agents within the past 3 months, including mycophenolate mofetil, hydroxychloroquine, cyclophosphamide, azathioprine, leflunomide, calcineurin inhibitors, and Chinese traditional medicines with immunosuppressive effects (such as Tripterygium wilfordii, Sinomenium acutum, Tripterygium Glycosides Tablets, Kunxian Capsules, Kunming Shanhaitang Tablets, etc.); treatment with B-cell targeted biological agents (such as telitacicept, etc.); complement pathway inhibitors, etc.;\n* Poorly controlled diabetes mellitus (HbA1c\\>8%）\n* Poorly controlled hypertension （≥160\u002F100mmHg）\n* Participants taking potent inhibitors of cytochrome P450 (CYP) 3A4.\n* Females who are pregnant, breastfeeding, or plan to become pregnant in the trial period.\n* Any other conditions that, in the investigator's judgment, make the patient ineligible for this clinical study.",{"count":268,"type":21},288,[270],"PHASE4","IgA nephropathy (IgAN) is a chronic progressive kidney disease, and long-term control of proteinuria and prevention of relapse are crucial for delaying disease progression. Patients with IgAN who achieve proteinuria remission after receiving Nefecon for 9 months or longer still face the risk of proteinuria relapse after treatment discontinuation. This study is to evaluate the efficacy and safety of Nefecon 8 mg treatment for 15 months as a maintenance therapy for prevention of proteinuria relapse in proteinuria-remitted patients.",[273],"IgA Nephropathy (IgAN)",{"date":230,"type":32},{"date":276,"type":21},"2026-05-01",{"date":60,"type":21},{"name":38,"class":39},{"id":280,"slug":281,"hasResults":12,"nctId":282,"briefTitle":283,"officialTitle":284,"acronym":285,"eligibilityCriteria":286,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":197,"enrollmentInfo":287,"targetDuration":4,"studyType":22,"phases":289,"briefSummary":290,"conditions":291,"keywords":293,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":302,"locationsCount":90},"100632300","phase-2-beta-blockers-on-the-efficacy-of-neoadjuvant-immunotherapy-for-gastric-cancer-100632300","NCT07511894","Beta-Blockers on the Efficacy of Neoadjuvant Immunotherapy for Gastric Cancer","Efficacy and Safety of Beta-Blockers Combined With Neoadjuvant Immunotherapy for Locally Advanced Gastric Cancer: an Open-lable, Single-arm Study","BBNIGC","Inclusion Criteria:\n\nVoluntarily sign the informed consent form;\n\nAged 18-75 years;\n\nECOG performance status 0-1;\n\nEither sex;\n\nPatients with a standardized histopathological diagnosis of gastric adenocarcinoma from the primary gastric lesion via endoscopic biopsy, according to the 15th edition of the Japanese Classification of Gastric Carcinoma (2017);\n\nPatients judged by the treating physician to require preoperative immune checkpoint inhibitor therapy, followed by potentially curative gastrectomy;\n\nMeet the diagnostic criteria for hypertension according to the 2023 Chinese Guidelines for the Management of Hypertension (systolic blood pressure ≥140 mmHg and\u002For diastolic blood pressure ≥90 mmHg, or a previous diagnosis of uncontrolled hypertension), with an indication for beta-blocker use;\n\nDeemed by a specialist to have no contraindications for beta-blocker use and can use beta-blockers for antihypertensive therapy.\n\nExclusion Criteria:\n\nHER2-positive or microsatellite instability-high (MSI-H)\u002FdMMR gastric cancer confirmed by immunohistochemistry;\n\nActive autoimmune disease requiring continuous immunosuppressive therapy or history of transplantation;\n\nCurrently receiving systemic immunosuppressive medication: If a patient is currently using corticosteroids, the corticosteroid dose must be ≤ equivalent of prednisone 10 mg daily;\n\nHistory of (non-infectious) pneumonitis\u002Finterstitial lung disease requiring treatment;\n\nConcurrent infection with human immunodeficiency virus (HIV);\n\nPregnant or breastfeeding women;\n\nHistory of psychiatric disorders;\n\nConcurrent other malignancies or severe organ dysfunction;\n\nPresence of contraindications for beta-blocker use (e.g., severe bradycardia, uncontrolled depression, unstable angina, uncontrolled heart failure (Class III or IV), hypotension (systolic blood pressure \\\u003C100 mmHg), severe asthma or chronic obstructive pulmonary disease (COPD), symptomatic peripheral arterial disease or Raynaud's syndrome, untreated pheochromocytoma, etc.);\n\nRefractory hypertension;\n\nJudged by the investigator as not meeting the inclusion criteria for this study",{"count":288,"type":21},33,[102],"Study Population:Patients with locally advanced gastric cancer complicated by hypertension, who are scheduled to undergo laparoscopic gastric cancer resection after receiving preoperative immunotherapy.\n\nPrimary Objective: To investigate the impact of combined beta-blocker use on the efficacy of immunotherapy in patients with locally advanced gastric cancer.\n\nSecondary Objective: To investigate the impact of combined beta-blocker use on the incidence of immune-related adverse events.\n\nStudy Groups:This study does not include a parallel control group; it enrolls only a single study group.\n\nStudy Design:This is a single-arm, exploratory clinical study. Study Duration:2026 - 2029 Sample Size: Single-arm, exploratory trial, planned enrollment of 33 cases.\n\nInclusion Criteria:\n\n* Voluntarily sign the informed consent form;\n* Aged 18-75 years;\n* ECOG performance status 0-1;\n* Either sex;\n* Patients with a standardized histopathological diagnosis of gastric adenocarcinoma from the primary gastric lesion via endoscopic biopsy, according to the 15th edition of the Japanese Classification of Gastric Carcinoma (2017);\n* Patients judged by the treating physician to require preoperative immune checkpoint inhibitor therapy, followed by potentially curative gastrectomy;\n* Meet the diagnostic criteria for hypertension according to the 2023 Chinese Guidelines for the Management of Hypertension (systolic blood pressure ≥140 mmHg and\u002For diastolic blood pressure ≥90 mmHg, or a previous diagnosis of uncontrolled hypertension), with an indication for beta-blocker use;\n* Deemed by a specialist to have no contraindications for beta-blocker use and can use beta-blockers for antihypertensive therapy.\n\nExclusion Criteria\n\n* HER2-positive or microsatellite instability-high (MSI-H)\u002FdMMR gastric cancer confirmed by immunohistochemistry;\n* Active autoimmune disease requiring continuous immunosuppressive therapy or history of transplantation;\n* Currently receiving systemic immunosuppressive medication: If a patient is currently using corticosteroids, the corticosteroid dose must be ≤ equivalent of prednisone 10 mg daily;\n* History of (non-infectious) pneumonitis\u002Finterstitial lung disease requiring treatment;\n* Concurrent infection with human immunodeficiency virus (HIV);\n* Pregnant or breastfeeding women;\n* History of psychiatric disorders;\n* Concurrent other malignancies or severe organ dysfunction;\n* Presence of contraindications for beta-blocker use (e.g., severe bradycardia, uncontrolled depression, unstable angina, uncontrolled heart failure (Class III or IV), hypotension (systolic blood pressure \\\u003C100 mmHg), severe asthma or chronic obstructive pulmonary disease (COPD), symptomatic peripheral arterial disease or Raynaud's syndrome, untreated pheochromocytoma, etc.);\n* Refractory hypertension;\n* Judged by the investigator as not meeting the inclusion criteria for this study.\n\nEffectiveness Analysis Primary Endpoint: Proportion of patients with Tumor Regression Grade (TRG) \\\u003C 3 (AJCC criteria).\n\nSecondary Endpoints: 3-year overall survival (OS), 3-year progression-free survival (PFS); correlation with immunotherapy-related biomarkers (e.g., PD-L1 expression, cortisol, adrenocorticotropic hormone, tumor tissue ADRB1 expression, tumor tissue RNA sequencing, tumor immune microenvironment); treatment compliance (immunotherapy completion rate, surgery delay rate).\n\nSafety Analysis:Incidence and severity of adverse events. Statistical Analysis:This is an exploratory, single-arm, uncontrolled study. The pathological response rate is the primary evaluation indicator, with a planned enrollment of 33 cases. The sample size was calculated based on the single-sample rate estimation method. Referring to similar exploratory immunotherapy combination studies and considering clinical practice, the anticipated pathological response rate is 80%. Using a two-sided α=0.05 (95% confidence level) and the Clopper-Pearson exact method, the two-sided 95% confidence interval for 33 samples is \\[0.625, 0.918\\], with an interval width of 0.294, which meets the core objective of preliminarily verifying the efficacy trend of the \"standard immunotherapy + beta-blocker\" regimen. A 10% dropout rate is also accounted for, balancing recruitment feasibility with basic statistical estimation precision. Descriptive statistical analysis will be used to calculate point estimates and 95% confidence intervals for primary and secondary endpoints. Survival analysis will use the Kaplan-Meier method to plot 3-year OS and PFS curves.\n\nFollow-up:Follow-up will be conducted at 1, 3, 6, 9, 12, 15, 18, 21, 24, 30, and 36 months post-surgery.",[292],"Gastric Cancer",[292,294,295],"Immunotherapy","Beta-Blockers","2026-05-10",{"date":298,"type":32},"2026-05-12",{"date":300,"type":21},"2026-05-20",{"date":116,"type":21},{"name":38,"class":39},{"id":304,"slug":305,"hasResults":12,"nctId":306,"briefTitle":307,"officialTitle":308,"acronym":4,"eligibilityCriteria":309,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":310,"targetDuration":4,"studyType":22,"phases":312,"briefSummary":313,"conditions":314,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":322,"completionDateStruct":323,"leadSponsor":325,"locationsCount":90},"100636417","phase-2-nanocrystalline-megestrol-acetate-versus-placebo-for-anorexia-in-patients-with-unresectable-hepatocellular-carcinoma-receiving-tace-combined-with-targeted-and-immunotherapy-100636417","NCT07565415","Nanocrystalline Megestrol Acetate Versus Placebo for Anorexia in Patients With Unresectable Hepatocellular Carcinoma Receiving TACE Combined With Targeted and Immunotherapy","A Multicenter, Randomized, Controlled Phase II Clinical Trial of Nanocrystalline Megestrol Acetate Versus Placebo for Anorexia in Patients With Unresectable Hepatocellular Carcinoma Receiving TACE Combined With Targeted and Immunotherapy","Inclusion Criteria:\n\n* Patients with unresectable primary hepatocellular carcinoma (HCC) confirmed by imaging or histopathology\n* No previous receipt of immunotherapy and\u002For targeted drug therapy\n* Child-Pugh score ≤ 7\n* At least one measurable lesion per RECIST 1.1 criteria; lesions without prior radiotherapy, cryotherapy or other local treatment\n* Single intrahepatic lesion \\\u003C 10 cm, or fewer than 10 intrahepatic lesions with tumor burden \\\u003C 50%\n* Meet precachexia criteria: non-volitional weight loss ≤ 5% in 6 months, plus systemic inflammation (CRP \\> 5 mg\u002FL) or decreased appetite (FAACT-A\u002FCS-12 score ≤ 37 points)\n* Meet cachexia criteria: accompanied by decreased appetite or systemic inflammation, with either non-volitional weight loss \\> 5% in 6 months or BMI \\\u003C 18.5 kg\u002Fm² plus weight loss \\> 2%\n* Voluntarily participate and sign informed consent\n* Age ≥ 18 years, male or female\n* Able to swallow tablets normally\n* ECOG performance status 0 or 1\n* Life expectancy ≥ 12 weeks\n* Adequate major organ function without blood products or colony-stimulating factors within 14 days\n* Hematology: ANC ≥ 1.5×10⁹\u002FL, Hb ≥ 80 g\u002FL, PLT ≥ 50×10⁹\u002FL\n* Liver function: TBIL ≤ 1.5×ULN, AST\u002FALT ≤ 5.0×ULN, ALB ≥ 28 g\u002FL\n* Coagulation function: INR, PT or aPTT ≤ 1.5×ULN\n* Renal function: SCr ≤ 1.5×ULN or creatinine clearance ≥ 60 mL\u002Fmin\n* Urine protein ≤ 1+ or 24-hour urine protein \\\u003C 1.0 g\n* Cardiac function: LVEF ≥ 50%\n* Females of childbearing potential with negative pregnancy test within 3 days before first dosing\n* Fertile male and female patients agree to effective contraception from screening to 120 days after last study drug\n* HBV\u002FHCV infected patients receive stable antiviral therapy without drug interaction\n\nExclusion Criteria:\n\n* Active or untreated CNS metastases; inadequately controlled metastatic brain or leptomeningeal disease\n* Uncontrolled tumor-related pain\n* Thromboembolic disease, ascites or lower limb edema within 6 months\n* History of other malignancies within 5 years before randomization, except curable low-risk tumors\n* Unresolved adverse toxicities from prior antitumor therapy not recovered to ≤ Grade 1 (CTCAE v5.0), excluding alopecia\n* Pregnant, breastfeeding females or those planning pregnancy during the study\n* Any unstable medical, psychiatric or social condition that may interfere with study participation\n* Positive HIV infection\n* Major surgery within 28 days prior to randomization\n* Severe cardiovascular disease, myocardial infarction, unstable arrhythmia, angina or cerebrovascular events\n* Severe systemic infection within 4 weeks before dosing or active infection requiring systemic anti-infective treatment\n* Impaired gastrointestinal absorption, long-term tube feeding, parenteral nutrition or eating disorders\n* Concomitant use of other appetite-enhancing or weight-stimulating agents\n* Cushing's syndrome, adrenal or pituitary insufficiency, poorly controlled diabetes\n* Uncontrolled hypertension despite oral antihypertensive treatment\n* Esophagogastric varices, severe ulcers, gastrointestinal bleeding, obstruction, perforation or fistula within 6 months\n* Known hypersensitivity to any component of the investigational product\n* Any other condition considered inappropriate for enrollment by the investigator.",{"count":311,"type":21},88,[102],"Primary Objective: To evaluate the effect of nanocrystalline megestrol acetate versus placebo on body weight and appetite in patients with unresectable hepatocellular carcinoma receiving TACE combined with targeted and immunotherapy.Secondary Objectives: To evaluate the effect of nanocrystalline megestrol acetate versus placebo on quality of life, inflammatory markers, nutritional indicators, and psychological stress in patients with unresectable hepatocellular carcinoma receiving TACE combined with targeted and immunotherapy.Exploratory Objective: To explore the impact of nanocrystalline megestrol acetate versus placebo on survival benefit in patients with unresectable hepatocellular carcinoma receiving TACE combined with targeted and immunotherapy.",[315,316,317,318],"Hepatocellular Carcinoma (HCC)","Cachexia","Anorexia","Malnutrition","2026-04-27",{"date":321,"type":32},"2026-05-04",{"date":82,"type":21},{"date":324,"type":21},"2027-09-01",{"name":38,"class":39},{"id":327,"slug":328,"hasResults":12,"nctId":329,"briefTitle":330,"officialTitle":331,"acronym":4,"eligibilityCriteria":332,"healthyVolunteers":12,"sex":333,"minAge":18,"maxAge":197,"enrollmentInfo":334,"targetDuration":4,"studyType":22,"phases":336,"briefSummary":337,"conditions":338,"keywords":342,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":90},"100634443","phase-2-brain-radiotherapy-combined-with-dalpiciclib-and-endocrine-therapy-in-hr-positiveher2-negative-advanced-breast-cancer-with-brain-metastases-100634443","NCT07539753","Brain Radiotherapy Combined With Dalpiciclib and Endocrine Therapy in HR-Positive\u002FHER2-Negative Advanced Breast Cancer With Brain Metastases","A Single-Arm, Phase II Study of Brain Radiotherapy Combined With Dalpiciclib and Endocrine Therapy in HR-Positive\u002FHER2-Negative Advanced Breast Cancer Patients With Brain Metastases","Inclusion Criteria:\n\n* 1.Female patients aged 18 to 75 years, who are postmenopausal or premenopausal\u002Fperimenopausal, and meet at least one of the following conditions:\n\n  1. prior bilateral oophorectomy; or age ≥60 years; or\n  2. age \\\u003C60 years and postmenopausal status defined as at least 12 consecutive months of spontaneous amenorrhea without other pathological or physiological causes, with estradiol (E2) and follicle-stimulating hormone (FSH) levels within the postmenopausal range; or\n  3. premenopausal or perimenopausal women are also eligible if they are willing to receive treatment with an LHRH agonist during the study.\n* 2.Histologically or cytologically confirmed HR-positive, HER2-negative breast cancer in female patients, with evidence of locally recurrent or metastatic disease that is not amenable to curative surgery or radiotherapy, and with no clinical indication for chemotherapy.\n* HR-positive is defined as ER-positive and\u002For PR-positive, with ≥1% of tumor cells showing positive staining, as confirmed by the investigator at the study site.\n* HER2-negative is defined as IHC 0 or 1+, or ISH-negative, defined as a HER2\u002FCEP17 ratio \\\u003C2.0 or an average HER2 copy number \\\u003C4.0, as confirmed by the investigator at the study site.\n* 3.Presence of brain metastases confirmed by MRI, with at least one measurable intracranial lesion ≥1 cm according to RECIST version 1.1. Measurable extracranial disease is not required.\n* 4.ECOG performance status 0-2, and an estimated life expectancy of at least 12 weeks at the time of enrollment.\n* 5.If the patient is receiving corticosteroids, the corticosteroid dose must be stable or decreasing for at least 5 days before the brain gadolinium-enhanced MRI (Gd-MRI). This MRI must be performed within 28 days before enrollment. Patients who require an increased steroid dose before treatment, or who are receiving an unstable steroid dose, are not eligible.\n* 6.Screening laboratory values must meet the following criteria( and should be obtained within 14 days prior to registration)::\n\n  1. absolute neutrophil count (ANC) ≥ 1,500\u002Fmm³ (1.5 × 10\\^9\u002FL), without growth factor support within 14 days;\n  2. platelet count (PLT) ≥ 100,000\u002Fmm³ (100 × 10\\^9\u002FL), without corrective treatment within 7 days;\n  3. hemoglobin (Hb) ≥ 9 g\u002FdL (90 g\u002FL), without corrective treatment within 7 days;\n  4. serum creatinine (Scr) ≤ 1.5 × upper limit of normal (ULN), or creatinine clearance ≥ 60 mL\u002Fmin;\n  5. total bilirubin ≤ 1.5 × ULN;\n  6. aspartate aminotransferase (AST\u002FSGOT) and alanine aminotransferase (ALT\u002FSGPT) ≤ 2.5 × ULN, or ≤ 5 × ULN for patients with liver metastases.\n* 7.Prior stereotactic radiosurgery (SRS) or fractionated stereotactic radiotherapy (FSRT) is permitted, provided that the currently active measurable disease has not been previously treated with radiotherapy.\n* 8.Women of childbearing potential must have a negative serum pregnancy test within 7 days before enrollment and must agree to use a medically acceptable highly effective method of contraception during the study and for 1 year after the last dose of study treatment.\n* 9.Ability and willingness to signed the informed consent form prior to patient entry.\n\nExclusion Criteria:\n\n* 1.Prior pathological diagnosis of HER2-positive breast cancer.\n* 2.Prior disease progression on dalpiciclib in the metastatic setting.\n* 3.Primary endocrine resistance, defined as either:\n\n  1. disease recurrence or progression within 2 years of starting adjuvant endocrine therapy; or\n  2. disease progression within 6 months of first-line endocrine therapy for advanced or metastatic disease.\n* 4.Patients considered not suitable for endocrine therapy in the judgment of the investigator, including patients with symptomatic visceral disease, disseminated visceral involvement, or a risk of life-threatening complications in the short term, such as uncontrolled massive effusions (pleural, pericardial, or peritoneal), lymphangitic carcinomatosis of the lung, or \\>50% liver involvement.\n* 5.Presence of leptomeningeal metastases.\n* 6.Prior whole-brain radiotherapy (WBRT) .\n* 7.Any severe neurologic symptoms caused by central nervous system metastases.\n* 8.Pregnant or breastfeeding women.\n* 9.Any serious uncontrolled clinical disease or infection that, in the investigator's judgment, cannot be adequately controlled with appropriate treatment or may impair the patient's ability to tolerate study treatment, including but not limited to:\n\n  1. serious cardiovascular events such as syncope of cardiovascular origin, pathologic ventricular arrhythmias (including but not limited to ventricular tachycardia or ventricular fibrillation), or cardiac arrest;\n  2. end-stage renal disease;\n  3. severe liver disease;\n  4. active systemic bacterial infection.\n* 10.History of immunodeficiency, including HIV infection, active hepatitis B virus (HBV) infection, active hepatitis C virus (HCV) infection, other acquired or congenital immunodeficiency disorders, or prior organ transplantation.\n* 11.History of malignancy other than breast cancer.\n* 12.Inability to swallow oral medication, or presence of chronic diarrhea, intestinal obstruction, or other conditions that may interfere with the administration or absorption of study drugs.\n* 13.History of allergy or hypersensitivity to any study drug or any of its components.","FEMALE",{"count":335,"type":21},46,[102],"This is a prospective, open-label, exploratory clinical trial designed to evaluate the efficacy and safety of brain radiotherapy combined with dalpiciclib and endocrine therapy in HR-positive\u002FHER2-negative advanced breast cancer patients with brain metastases. A total of 46 patients are planned to be enrolled.\n\nParticipants will receive dalpiciclib plus endocrine therapy and brain radiotherapy, including fractionated stereotactic radiotherapy (FSRT) or whole-brain radiotherapy (WBRT), according to the clinical characteristics of brain metastatic lesions. Radiotherapy may start within 30 days before or after initiation of drug treatment. Dalpiciclib and endocrine therapy may be given concurrently during radiotherapy and will be continued after radiotherapy until disease progression, intolerable toxicity, withdrawal of informed consent, or investigator decision. Participants will visit the clinic once every 3 months for checkups and tests. Tumor response will be assessed according to RECIST version 1.1, and safety will be evaluated throughout the study.",[339,340,341],"Breast Cancer","Brain Metastases","HR+\u002FHER2- Breast Cancer",[341,343,344,345],"brain metastases","brain radiotherapy","dalpiciclib","2026-04-24",{"date":348,"type":32},"2026-04-30",{"date":350,"type":21},"2026-06-01",{"date":352,"type":21},"2029-08-01",{"name":38,"class":39},{"id":355,"slug":356,"hasResults":12,"nctId":357,"briefTitle":358,"officialTitle":359,"acronym":4,"eligibilityCriteria":360,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":98,"enrollmentInfo":361,"targetDuration":4,"studyType":22,"phases":363,"briefSummary":364,"conditions":365,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":369,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":375,"locationsCount":4},"100634779","effect-of-babao-dan-capsule-combined-with-antiviral-therapy-on-the-incidence-of-hepatocellular-carcinoma-in-patients-with-hepatitis-b-related-cirrhosis-100634779","NCT07544121","Effect of Babao Dan Capsule Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B-related Cirrhosis","Effect of Babao Dan Capsule Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B-related Cirrhosis: A Multicenter, Randomized, Placebo-controlled Study","Inclusion Criteria:\n\n1. Voluntarily signed informed consent form\n2. Aged 18-65 years\n3. Traditional Chinese Medicine (TCM) syndrome type of Shi-re-du-yun\n4. Meeting the diagnostic criteria for hepatitis B-related cirrhosis\n5. aMAP score \\> 60\n\nExclusion Criteria:\n\n1. Previously diagnosed with or treated for hepatocellular carcinoma (HCC) or other malignancies\n2. Pregnant or lactating women\n3. Decompensated cirrhosis (e.g., presence of obvious ascites, hepatic encephalopathy, or gastrointestinal bleeding)\n4. Concomitant liver diseases, including but not limited to hepatitis C virus infection, human immunodeficiency virus infection, alcoholic liver disease, autoimmune liver disease, or drug-induced liver injury\n5. Severe cardiac, renal, respiratory, or hematopoietic system diseases\n6. Determined by the investigator to be unsuitable for participation in this trial",{"count":362,"type":21},1034,[24],"This study aims to establish a prospective, multicenter, randomized, double-blind, placebo-controlled parallel-group clinical trial cohort. The cohort will include high-risk populations for hepatitis B cirrhosis-related hepatocellular carcinoma (HCC) from multiple centers nationwide, who meet the criteria of traditional Chinese medicine syndrome differentiation as Shi-re-du-yun syndrome and have an aMAP score \\>60 points. The objective is to evaluate whether combining Babao Dan Capsule with standard anti-hepatitis B virus therapy can further reduce the incidence of HCC in this high-risk population.",[366,367,315],"HEPATITIS B CHRONIC","Cirrhosis, Liver","2026-04-19",{"date":370,"type":32},"2026-04-22",{"date":372,"type":21},"2026-04-01",{"date":374,"type":21},"2028-11-30",{"name":38,"class":39},{"id":377,"slug":378,"hasResults":12,"nctId":379,"briefTitle":380,"officialTitle":381,"acronym":4,"eligibilityCriteria":382,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":197,"enrollmentInfo":383,"targetDuration":4,"studyType":177,"phases":4,"briefSummary":384,"conditions":385,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":387,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":394},"100605061","prospective-pathology-foundation-models-100605061","NCT07157618","Prospective Pathology Foundation Models","Development and Clinical Application of Deep Learning-Based Prospective Pathology Foundation Models","Inclusion Criteria:\n\n1. Aged 18-75 years old.\n2. Patients with complete pathological slides and clinical information.\n\nExclusion Criteria:\n\n1.Patients with missing data or specimens not meeting quality control requirements for analysis.",{"count":221,"type":21},"Histopathology remains the gold standard for disease diagnosis, yet faces challenges including pathologist shortages and diagnostic model limitations. This underscores the critical need to develop deep learning-based pathology foundation models integrating prospective imaging and clinical data. Such models would enhance diagnostic accuracy and efficiency, enabling tumor grading, histo-molecular classification, and intelligent chemotherapy guidance - ultimately optimizing clinical workflows. However, a critical gap remains: the absence of prospectively validated, pan-disease pathology foundation models. Developing clinically validated models is therefore imperative.",[386],"Pancancer",{"date":388,"type":32},"2026-04-23",{"date":390,"type":32},"2025-08-28",{"date":392,"type":21},"2028-08",{"name":38,"class":39},2,{"id":396,"slug":397,"hasResults":12,"nctId":398,"briefTitle":399,"officialTitle":400,"acronym":401,"eligibilityCriteria":402,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":403,"targetDuration":4,"studyType":177,"phases":4,"briefSummary":405,"conditions":406,"keywords":409,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":419,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":424,"locationsCount":90},"100634212","comparison-of-the-efficacy-and-safety-of-ciprofol-versus-propofol-for-sedation-in-icu-patients-undergoing-non-invasive-ventilation-100634212","NCT07536750","Comparison of the Efficacy and Safety of Ciprofol Versus Propofol for Sedation in ICU Patients Undergoing Non-Invasive Ventilation","Comparison of the Efficacy and Safety of Ciprofol Versus Propofol for Sedation in ICU Patients Undergoing Non-Invasive Ventilation: A Multicenter Retrospective Cohort Study","CALM-ICU","Inclusion Criteria Age:\n\n* Age ≥18 years\n* Admitted to the intensive care unit (ICU) between January 1, 2022 and July 30, 2024\n* Received intravenous sedation with either ciprofol or propofol during ICU stay\n* Total duration of ciprofol or propofol administration ≥2 hours\n* Sedation initiated while the patient was not receiving invasive mechanical ventilation\n* Receiving non-invasive respiratory support or oxygen therapy at the time sedation was started, including noninvasive ventilation (NIV), high-flow nasal cannula (HFNC), nasal cannula, or face mask oxygen therapy\n* Availability of complete electronic medical records including sedation assessment using the Richmond Agitation-Sedation Scale (RASS)\n* Availability of continuous vital sign monitoring records including respiratory rate, oxygen saturation, blood pressure, and heart rate\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Pregnancy or breastfeeding\n* Use of other primary sedative agents during the observation period, including midazolam or dexmedetomidine\n* Total exposure time to ciprofol or propofol \\\u003C2 hours\n* Known allergy or hypersensitivity to ciprofol, propofol, or their formulation components\n* Initiation of invasive mechanical ventilation before sedation\n* Missing key clinical data required for outcome evaluation, including sedation score, vital signs, or drug administration records\n* Participation in other interventional clinical trials that may interfere with outcome assessment\n* Severe visual or hearing impairment preventing accurate sedation assessment\n* Coma or conditions that prevent reliable evaluation using the Richmond Agitation-Sedation Scale (RASS)\n* Any condition that the investigators consider inappropriate for inclusion in the study",{"count":404,"type":21},1680,"Sedation is frequently required in critically ill patients admitted to the intensive care unit (ICU), including those receiving non-invasive respiratory support such as high-flow nasal cannula (HFNC), non-invasive ventilation (NIV), or conventional oxygen therapy. Anxiety, agitation, dyspnea, and poor tolerance of respiratory support may compromise treatment adherence and increase the risk of respiratory deterioration and endotracheal intubation. Appropriate sedation may improve patient comfort, facilitate respiratory support, and reduce complications. However, sedation in non-mechanically ventilated ICU patients remains challenging because excessive sedation may lead to respiratory depression or hemodynamic instability.\n\nPropofol is commonly used for ICU sedation because of its rapid onset and controllable depth of sedation. Nevertheless, propofol is associated with several adverse effects, including respiratory depression, hypotension, and injection pain, which may limit its use in patients without invasive mechanical ventilation.\n\nCiprofol is a novel short-acting intravenous sedative that acts as a gamma-aminobutyric acid type A (GABA-A) receptor agonist and is structurally related to propofol. Previous studies have demonstrated that ciprofol has rapid onset, predictable sedation, less injection pain, and a potentially lower incidence of respiratory depression and hemodynamic instability compared with propofol. Clinical studies have shown favorable safety and efficacy profiles of ciprofol in procedural sedation, anesthesia induction, and sedation in mechanically ventilated ICU patients. However, evidence regarding its use in ICU patients receiving non-mechanical ventilation is still limited.\n\nThis study aims to compare the effectiveness and safety of ciprofol versus propofol for sedation in adult ICU patients who are not receiving invasive mechanical ventilation. The study will be conducted as a multicenter retrospective cohort study involving approximately 30 tertiary hospitals in China. Adult ICU patients treated between January 1, 2022 and July 30, 2024 who received intravenous sedation with either ciprofol or propofol while receiving non-invasive respiratory support (including NIV, HFNC, or conventional oxygen therapy) will be included.\n\nThe primary outcomes are sedation success rate and the incidence of respiratory depression. Sedation success is defined as maintaining the Richmond Agitation-Sedation Scale (RASS) within the target range of -2 to +1 for at least two consecutive hours without discontinuation of the sedation regimen or switching to another sedative. Respiratory depression will be defined based on predefined criteria including severe hypoxemia, markedly reduced respiratory rate, abnormal end-tidal carbon dioxide levels, or apnea.\n\nSecondary outcomes include endotracheal intubation rate during the sedation period, ICU length of stay, ICU mortality, and the requirement for vasoactive agents. Propensity score matching and multivariable statistical models will be used to adjust for baseline differences and potential confounders between treatment groups.\n\nThis real-world study aims to provide evidence regarding the clinical effectiveness and respiratory safety of ciprofol compared with propofol for sedation in ICU patients without invasive mechanical ventilation. The findings may help optimize sedation strategies in critically ill patients receiving non-invasive respiratory support and provide evidence to support future prospective clinical trials.",[407,408],"Respiratory Failure","Critical Illness",[410,411,412,413,414,415,416,417],"Ciprofol","Propofol","ICU Sedation","Noninvasive Ventilation","High-Flow Nasal Cannula","Respiratory Depression","Sedation Safety","Critical Care","2026-04-15",{"date":420,"type":32},"2026-04-17",{"date":422,"type":32},"2025-11-24",{"date":56,"type":21},{"name":38,"class":39},{"id":426,"slug":427,"hasResults":12,"nctId":428,"briefTitle":429,"officialTitle":429,"acronym":4,"eligibilityCriteria":430,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":197,"enrollmentInfo":431,"targetDuration":4,"studyType":177,"phases":4,"briefSummary":433,"conditions":434,"keywords":437,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":441,"startDateStruct":443,"completionDateStruct":445,"leadSponsor":447,"locationsCount":448},"100634629","clinical-outcomes-after-non-curative-endoscopic-resection-in-early-colorectal-cancer-a-multicenter-study-100634629","NCT07542171","Clinical Outcomes After Non-curative Endoscopic Resection in Early Colorectal Cancer: A Multicenter Study","Inclusion Criteria:\n\n* Age ≥18 years;\n* Patients with early colorectal cancer confirmed by histopathology;\n* Patients who underwent endoscopic resection (including EMR, ESD, or equivalent techniques);\n* Pathological diagnosis indicating non-curative resection, defined by the presence of at least one of the following: positive resection margin, submucosal invasion depth \\>1000 μm, poor differentiation, lymphovascular invasion, perineural invasion, or high-grade tumor budding;\n* Availability of complete clinicopathological and follow-up data;\n* Patients managed with either additional surgery or surveillance after endoscopic resection.\n\nExclusion Criteria:\n\n* Patients with synchronous advanced colorectal cancer or distant metastasis at baseline;\n* History of other active malignancies;\n* Patients with inflammatory bowel disease, familial adenomatous polyposis, or other hereditary colorectal cancer syndromes;\n* Patients who received neoadjuvant therapy before endoscopic resection;\n* Incomplete pathological data or missing key variables;\n* Loss to follow-up or follow-up duration less than 6 months.",{"count":432,"type":21},400,"This multicenter study aims to evaluate clinical outcomes and optimize management strategies in patients with early colorectal cancer who undergo non-curative endoscopic resection.\n\nPatients with non-curative resection following endoscopic treatment will be enrolled across multiple centers and managed according to real-world clinical decisions, including additional surgery or surveillance. Baseline demographic, endoscopic, and pathological characteristics will be systematically collected.\n\nThe primary objective is to compare recurrence and survival outcomes between different management strategies. Secondary objectives include identifying prognostic factors associated with recurrence and developing a risk stratification model to guide individualized treatment decisions.\n\nAll participants will undergo standardized follow-up according to clinical guidelines. This study is expected to provide real-world evidence to refine risk assessment, reduce unnecessary surgery, and improve personalized management for patients with early colorectal cancer after non-curative endoscopic resection.",[435,436],"Early Colorectal Cancer","Non-curative Endoscopic Resection",[438,439],"Early colorectal cancer","Non-curative resection","2026-04-14",{"date":442,"type":32},"2026-04-21",{"date":444,"type":32},"2025-09-03",{"date":446,"type":21},"2028-12-01",{"name":38,"class":39},3,{"id":450,"slug":451,"hasResults":12,"nctId":452,"briefTitle":453,"officialTitle":454,"acronym":4,"eligibilityCriteria":455,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":456,"targetDuration":4,"studyType":22,"phases":458,"briefSummary":459,"conditions":460,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":466,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":90},"100634291","phase-2-benmelstobart-plus-anlotinib-combined-with-sbrt-for-patients-with-hepatocellular-carcinoma-failing-first-line-targeted-therapy-100634291","NCT07537777","Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted Therapy","Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted Therapy:A Single-Arm, Multicenter Clinical Study","Inclusion Criteria:\n\n1. The patients voluntarily participated in the study, signed the informed consent form, and the compliance was good.\n2. Age \\>=18 years old, male or female;\n3. Patients with histologically confirmed or clinically diagnosed HCC, and the disease is not suitable for radical surgery;\n4. Patients with oligometastatic HCC who had failed previous target-immunotherapy combined with first-line therapy. Oligometastases are defined as the number of metastatic organs ≤2 and the total number of metastases \\\u003C=5, and oligometastases are suitable for SBRT treatment.\n5. Child-Pugh liver function score \\\u003C=7;\n6. ECOG score of 0-1;\n7. Expected survival time before initiation of study drug \\>=12 weeks;\n8. At least one measurable lesion (the long diameter of the measurable lesion on enhanced spiral CT or enhanced MR Scan \\>=10mm or the short diameter of the enlarged lymph node \\>=15mm according to RECISTv1.1; a lesion that has been treated with previous radiotherapy can be considered as a target lesion after definite progression according to RECISTv1.1 criteria);\n9. The following laboratory tests performed within 7 days before the first dose of medication confirmed that the patient's bone marrow, liver and kidney function met the following requirements for study participation: 1) hemoglobin \\>=80 g\u002FL (which can be maintained or exceeded by transfusion); 2) absolute neutrophil count (ANC) \\>=1.5×10\\^9; 3) platelet count \\>=50×10\\^9\u002Fmm3; 4) Total bilirubin \\\u003C=1.5 times upper limit of normal; 5) alanine aminotransferase and aspartate aminotransferase \\\u003C=2.5 times upper limit of normal (ULN); 6) creatinine \\\u003C=1.5 times upper limit of normal (ULN); And creatinine clearance \\>=60ml\u002Fmin; 7) international normalized ratio (INR) of prothrombin time \\\u003C=1.5 in patients without previous anticoagulant therapy; Partial thromboplastin time (APTT)\\\u003C=1.5 times the upper limit of normal; 8) if HBV-DNA is detectable, antiviral therapy should be started before enrollment; 9) If HCV-RNA is detectable, antiviral therapy should be started before enrollment.\n10. Women of childbearing age: must agree to abstain from sexual intercourse (heterosexual intercourse) or use a reliable, effective method of contraception for at least 120 days from the time of written informed consent until the last dose of study drug is administered. A serum HCG test had to be negative within 7 days before starting study treatment; And they must be non-lactating. Women were considered to be fertile if they had menstruated, had not yet reached a postmenopausal state (\\>=12 months of continuous absence of menses, with no cause other than menopause identified), and had not undergone sterilization procedures (e.g., hysterectomy, bilateral tubal ligation, or bilateral oophorectomy).\n11. Male patients whose partner was a woman of reproductive age had to agree to abstain from sex or to use a reliable, effective method of contraception for at least 120 days from the time of written informed consent until the last dose of study drug was administered. Male patients also had to agree not to donate sperm during the same period. Male subjects whose partner was pregnant were required to use condoms.\n\nExclusion Criteria:\n\n1. Known cholangiocarcinoma, sarcomatoid HCC, mixed cell carcinoma, and fibrolamellar cell carcinoma. Other active malignant tumors other than HCC within 5 years or at the same time. The cured localized tumors, such as skin basal cell carcinoma, skin squamous cell carcinoma, superficial bladder cancer, prostate cancer in situ, cervical cancer in situ, breast cancer in situ, etc., were excluded.\n2. Prior receipt of anlotinib or a non-PD-1 monoclonal antibody immune checkpoint inhibitor;\n3. The time interval between the last target-free drug use and enrollment was less than 3 weeks.\n4. Patients who received previous local treatment (including TACE, ablation, HAIC, or radiotherapy) for the target lesion less than 1 month before enrollment.\n5. Patients preparing for or previously receiving organ or allogeneic bone marrow transplantation;\n6. Moderate or severe ascites with clinical symptoms, which required therapeutic puncture, drainage or Child-Pugh score \\>2 (except for patients with small amount of ascites on imaging but without clinical symptoms); Uncontrolled or moderate or above amount of pleural effusion and pericardial effusion;\n7. A history of gastrointestinal bleeding within 6 months before the initiation of study treatment or a definite tendency for gastrointestinal bleeding, such as: Patients with risk of bleeding or severe esophagogastric varices, local active gastrointestinal ulcer lesions, and persistent positive fecal occult blood were excluded (patients with positive fecal occult blood at baseline could be re-examined, and patients with positive fecal occult blood after re-examination required gastroduodenoscopy (EGD). Patients with esophagogastric varices with a risk of bleeding were excluded).\n8. Abdominal fistula, gastrointestinal perforation, or abdominal abscess within 6 months before study treatment;\n9. Known inherited or acquired bleeding (e.g., coagulopathy) or thrombophilia, as in hemophilia patients;\n10. Current or recent (within 10 days before initiation of study treatment) use of a full-dose oral or injectable anticoagulant or thrombolytic agent for therapeutic purposes (prophylactic use of low-dose aspirin and low-molecular-weight heparin was allowed);\n11. Currently using or recently using (within 10 days before initiation of study treatment) aspirin (\\> 325 mg\u002F day (maximum antiplatelet dose) or dipyridamole, ticlopidine, clopidogrel, and cilostazol; Thrombotic or embolic events, such as cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), pulmonary embolism, etc., occurred within 6 months before the initiation of study treatment;\n12. There are not well controlled cardiac clinical symptoms or diseases, such as: (1) according to the New York Heart Association (NYHA) criteria (see Annex 5) grade II or higher cardiac dysfunction or cardiac ultrasound examination: Left ventricular ejection fraction (LVEF) \\\u003C50% (2) unstable heartache (3) myocardial infarction within 1 year before study treatment (4) clinically significant supraventricular or ventricular arrhythmia requiring treatment or intervention (5) QTc \\> 450ms (male); QTc \\> 470ms (female) (QTc interval was calculated with Fridericia's formula; if QTc was abnormal, three consecutive tests could be performed at a 2-minute interval, and the mean value was calculated);\n13. Hypertension that is not well controlled with antihypertensive medication (systolic blood pressure \\>=140 mmHg or diastolic blood pressure ≥90 mmHg) (based on the mean of \\>=2 readings), and the use of antihypertensive treatment to achieve these parameters is permitted; A history of hypertensive crisis or hypertensive encephalopathy;\n14. Major vascular disease within 6 months before starting study treatment (e.g., aortic aneurysm requiring manual repair or recent peripheral artery thrombosis);\n15. Severe, unhealed or dehiscence wounds and active ulcers or untreated bone fractures;\n16. Major surgery (other than diagnosis) within 4 weeks before the start of study treatment or anticipated need for major surgery during the study;\n17. Inability to swallow tablets, malabsorption syndrome or any condition affecting gastrointestinal absorption;\n18. Had intestinal obstruction and\u002For had clinical signs or symptoms of GI obstruction within 6 months before starting study treatment, including incomplete obstruction related to a preexisting disease or requiring routine parenteral hydration, parenteral nutrition, or tube feeding: Patients with incomplete obstruction\u002Fobstruction syndrome\u002Fintestinal obstruction signs\u002Fsymptoms at initial diagnosis were allowed to enroll if definitive (surgical) treatment was given to resolve the symptoms;\n19. Evidence of pneumoperitoneum that could not be explained by paracentesis or recent surgical procedures;\n20. Metastatic disease involving a major airway or blood vessel (e.g., complete occlusion of the main portal vein or vena cava due to tumor invasion, which was defined as the confluence of the splenic vein and the superior mesenteric vein or the branch of the hepatic portal vein into left and right branches) or a centrally located large mediastinal tumor mass (\\\u003C30mm from the carinal crest) were excluded. The liver lesions were more than 50% occupied.\n21. The patient presented with active symptomatic central nervous system metastases or hepatic encephalopathy;\n22. Those who have had or are currently having interstitial pneumonia or interstitial lung disease, or a previous history of interstitial pneumonia or interstitial lung disease requiring steroid therapy, or other pulmonary fibrosis, organizing pneumonia (e.g., Bronchiolitis obliterans), pneumoconiosis, drug-related pneumonia, idiopathic pneumonia, or evidence of active pneumonia or severe impairment of lung function on chest computed tomography (CT) during the screening period were allowed to have radiation pneumonia in the radiation field. Active tuberculosis;\n23. Have active autoimmune disease or a history of autoimmune disease with possible recurrence (including but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism \\[subjects controlled only with hormone replacement therapy are eligible\\]); Subjects with skin diseases without systemic treatment such as vitiligo, psoriasis, alopecia, controlled type I diabetes treated with insulin, or asthma that had been completely relieved in childhood and without any intervention in adulthood were included. Patients with asthma who required medical intervention with bronchodilators were excluded.\n24. Use of immunosuppressive or systemic hormonal therapy for immunosuppression within 14 days prior to initiation of study treatment (at a dose of \\>10mg\u002F day of prednisone or other equivalent);\n25. Use of strong CYP3A4\u002F CYP2C19 inducers including rifampicin (and its analogues) and St. John's ST. or strong CYP3A4\u002F CYP2C19 inhibitors within 14 days before starting study treatment;\n26. Known to have a history of severe allergy to any monoclonal antibody or anti-angiogenesis targeted drugs;\n27. Severe infection within 4 weeks before starting study treatment, including, but not limited to, hospitalization for infection, bacteremia, or complications of severe pneumonia; Therapeutic oral or intravenous antibiotics within 2 weeks before starting study treatment (patients receiving prophylactic antibiotics (e.g., to prevent urinary tract infection or exacerbations of chronic obstructive pulmonary disease were eligible);\n28. Patients with congenital or acquired immune deficiency (such as HIV infection);\n29. Patients who had received traditional Chinese medicine (TCM) with anti-tumor therapeutic effect less than two weeks before enrollment (TCM containing the following herbs, such as brucea javanica, Coix seed, lentinus edodes polysaccharide, cantharides, bui skin, Astragalus, Kushen, Wu Guteng, Chebulae, icaritin, etc.);\n30. Received live attenuated vaccine within 28 days before starting study treatment;\n31. Received other trial medication within 21 days before starting study treatment;\n32. Pregnant or lactating women;\n33. According to the investigator's judgment, the patient has other factors that may affect the study results or lead to the forced termination of the study, such as alcohol abuse, drug abuse, other serious diseases (including mental diseases) requiring combined treatment, serious laboratory test abnormalities, accompanied by family or social factors, which will affect the safety of the patient.",{"count":457,"type":21},29,[102],"This prospective, single-arm, multicenter Phase II clinical trial aims to evaluate the efficacy and safety of Benmelstobart plus anlotinib combined with SBRT in patients with oligometastatic hepatocellular carcinoma who have failed first-line targeted therapy. Key study questions include: What is the progression-free survival (PFS) for patients treated with this regimen? How do the objective response rate (ORR), disease control rate (DCR), and overall survival (OS) compare? What are the safety and tolerability profiles of the combination therapy? Eligible subjects (after signing informed consent) will receive anlotinib 10mg on days 1-14 every 3 weeks + Benmelstobart 1200mg on day 1 every 3 weeks + SBRT. Treatment cycles will be 3 weeks long, continuing until a protocol-specified treatment discontinuation event occurs. Following treatment completion, subjects will undergo post-treatment safety follow-up and survival monitoring, with tumor progression monitoring conducted post-treatment.",[315,461,462,463,161,464],"First-line Targeted Therapy Failure","Oligometastatic Hepatocellular Carcinoma","Benmelstobart","SBRT","2026-04-13",{"date":420,"type":32},{"date":468,"type":21},"2026-04-20",{"date":470,"type":21},"2028-08-31",{"name":38,"class":39},{"id":473,"slug":474,"hasResults":12,"nctId":475,"briefTitle":476,"officialTitle":476,"acronym":477,"eligibilityCriteria":478,"healthyVolunteers":12,"sex":17,"minAge":479,"maxAge":480,"enrollmentInfo":481,"targetDuration":4,"studyType":22,"phases":483,"briefSummary":484,"conditions":485,"keywords":489,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":493,"startDateStruct":494,"completionDateStruct":495,"leadSponsor":497,"locationsCount":498},"100634446","phase-2-efficacy-and-safety-evaluation-of-absorbable-and-moldable-skull-base-support-plates-in-extended-endoscopic-endonasal-transsphenoidal-surgery-a-prospective-randomized-controlled-study-100634446","NCT07539792","Efficacy and Safety Evaluation of Absorbable and Moldable Skull Base Support Plates in Extended Endoscopic Endonasal Transsphenoidal Surgery: A Prospective, Randomized, Controlled Study","EEEA-AMSBP","Inclusion Criteria:\n\n1. Aged 1-80 years, regardless of gender;\n2. Diagnosed with sellar region tumors confirmed by clinical symptoms, endocrine examinations, and imaging data;\n3. Planned to undergo extended endoscopic endonasal transsphenoidal approach surgery as determined by departmental discussion;\n4. Karnofsky Performance Status score ≥ 70, with an expected survival period ≥ 24 months;\n5. Laboratory indicators (such as liver and kidney function, blood routine, etc.) within the normal range or controllable range;\n6. Sign the informed consent form and are willing to participate in the study.\n\nExclusion Criteria:\n\n1. Patients with other concurrent intracranial tumors or severe brain lesions;\n2. Patients scheduled to undergo craniotomy or non-extended endoscopic endonasal transsphenoidal surgery;\n3. Patients with uncontrolled severe heart, lung, kidney, or liver diseases;\n4. Pregnant or lactating women;\n5. Patients who have previously received radiotherapy or chemotherapy;\n6. Patients with active nasal infections, inflammation, or severe nasal diseases;\n7. Patients with a history of severe allergies to drugs or synthetic materials;\n8. Patients with extensive skull base bone destruction evaluated by preoperative imaging, for whom it is estimated that support materials cannot be used during surgery;\n9. Patients with mental illness or cognitive impairment who are unable to complete follow-up or understand the purpose of the study.","1 Year","80 Years",{"count":482,"type":21},126,[102],"Primary objective: To evaluate the effect of absorbable and moldable skull base support plates used in extended endoscopic endonasal transsphenoidal surgery on the incidence of cerebrospinal fluid (CSF) rhinorrhea within 1 month after surgery.\n\nSecondary objectives:\n\n1. To evaluate the effect of absorbable and moldable skull base support plates used in extended endoscopic endonasal transsphenoidal surgery on the incidence of intracranial infection within 1 months after surgery;\n2. To evaluate the effect of absorbable and moldable skull base support plates used in extended endoscopic endonasal transsphenoidal surgery on the duration of the surgery and length of postoperative hospital stay;\n3. To monitor and evaluate the safety of absorbable and moldable skull base support plates, especially the occurrence of nasal complications.",[486,487,488],"Sellar Tumor","Endonasal Surgery","Csf Leakage",[486,490,491,492],"Extended Endoscopic Endonasal Transsphenoidal Surgery","Cerebrospinal Fluid Rhinorrhea","Skull Base Reconstruction",{"date":468,"type":32},{"date":372,"type":32},{"date":496,"type":21},"2030-02-28",{"name":38,"class":39},8,{"id":500,"slug":501,"hasResults":12,"nctId":502,"briefTitle":503,"officialTitle":503,"acronym":4,"eligibilityCriteria":504,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":152,"enrollmentInfo":505,"targetDuration":507,"studyType":177,"phases":4,"briefSummary":508,"conditions":509,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":511,"startDateStruct":512,"completionDateStruct":514,"leadSponsor":516,"locationsCount":90},"100634441","clinical-value-of-intestinal-ultrasound-in-predicting-clinical-relapse-in-crohns-disease-patients-in-deep-remission-a-multicenter-prospective-observational-study-100634441","NCT07539727","Clinical Value of Intestinal Ultrasound in Predicting Clinical Relapse in Crohn's Disease Patients in Deep Remission: a Multicenter Prospective Observational Study","Inclusion Criteria:\n\n* Patients previously diagnosed with Crohn's disease via endoscopy and histopathology at other hospitals or at our institution; patients aged 18-70 years; Complete clinical data and biochemical parameters are available for the week before and after endoscopy, including comprehensive patient demographics and laboratory indicators such as complete blood count, liver function, kidney function, CRP, and ESR; a color Doppler ultrasound of the intestines was performed at our hospital within one week before or after endoscopy, and the relevant records are complete; patients assessed to have achieved deep remission based on endoscopic and other data.\n\nExclusion Criteria:\n\n* Patients with concomitant colorectal cancer; patients with severe cardiovascular, respiratory, or urinary dysfunction; pregnant or lactating women; patients younger than 16 or older than 70 years of age; patients who changed their maintenance therapy regimen upon achieving deep remission; patients with incomplete medical records, such as color Doppler ultrasound of the intestines.",{"count":506,"type":21},420,"18 Months","Crohn's disease (CD) is a nonspecific chronic inflammatory condition characterized by a protracted course with alternating periods of relapse and remission. Even patients who achieve deep remission remain prone to recurrence and require long-term follow-up. While various monitoring methods are available, endoscopy plays a primary role in the management and diagnosis of CD; however, its relative invasiveness and the need for bowel preparation limit the feasibility of continuous monitoring. In contrast, transabdominal intestinal ultrasound offers advantages such as non-invasiveness, absence of radiation, good patient tolerance, and low cost, making it suitable for long-term monitoring. However, most studies have focused on exploring its concordance with disease activity and endoscopic findings, with only a limited number of studies examining its clinical significance for long-term prognosis.\n\nTherefore, we conducted a multicenter prospective study involving 18 months of follow-up in CD patients who achieved deep remission. Based on the follow-up results, patients were divided into relapse and non-relapse groups. Stratified analysis was performed according to the Montreal classification to compare color Doppler ultrasound parameters between the two groups and within each stratum, and to establish a predictive model.",[510],"Inflammatory Bowel Diseases",{"date":468,"type":32},{"date":513,"type":32},"2025-01-01",{"date":515,"type":21},"2029-01-01",{"name":38,"class":39},{"id":518,"slug":519,"hasResults":12,"nctId":520,"briefTitle":521,"officialTitle":522,"acronym":4,"eligibilityCriteria":523,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":98,"enrollmentInfo":524,"targetDuration":4,"studyType":22,"phases":526,"briefSummary":527,"conditions":528,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":530,"startDateStruct":531,"completionDateStruct":532,"leadSponsor":533,"locationsCount":90},"100634445","phase-2-luspatercept-in-preventing-poor-erythroid-engraftment-for-hematological-malignancies-with-moderate-to-severe-myelofibrosis-100634445","NCT07539779","Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis","The Efficacy and Safety of Luspatercept in Preventing Poor Erythroid Engraftment After Allo-HSCT for Hematological Malignancies With Moderate to Severe Myelofibrosis: A Prospective, Multicenter, Randomized Controlled Study","Inclusion Criteria:\n\n* Age 18-65 years old, gender not restricted;\n* ECOG score 0-2 points;\n* Hematological malignancies with moderate to severe myelofibrosis\n* Willing to undergo the first allo-HSCT with a suitable donor\n* In a CR state before transplantation.\n\nExclusion Criteria:\n\n* Has previously undergone allo-HSCT;\n* ECOG score is 3-5;\n* Expected lifespan after transplantation is less than 30 days;\n* Has severe cardiac dysfunction, severe arrhythmia or severe pulmonary dysfunction (obstructive and\u002For restrictive ventilation disorder);\n* Has severe liver dysfunction, with liver function indicators (aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin (TBIL)) more than twice the upper limit of normal;\n* Has severe renal dysfunction, with creatinine (Cr) more than twice the upper limit of normal or 24-hour creatinine clearance rate (Ccr) lower than 30 ml\u002Fmin;\n* Has severe active bleeding;\n* Patients judged by the investigator to be unsuitable for participating in this trial.",{"count":525,"type":21},196,[102,103],"Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an important treatment for hematological malignancies. Poor erythroid engraftment after transplantation is a serious complication, especially in patients with moderate to severe myelofibrosis (MF). Currently, there is a lack of effective prevention strategies for poor erythroid engraftment after transplantation. Luspatercept, a novel TGF-β superfamily signaling pathway modulator, has shown potential in small-sample studies for the treatment and prevention of post-transplant anemia. Given the high proportion and poor prognosis of poor engraftment function in hematological malignancies with moderate to severe myelofibrosis after transplantation, we plan to conduct a prospective, multicenter, randomized controlled study to explore the efficacy and safety of luspatercept in preventing poor erythroid engraftment after allo-HSCT in hematological malignancies with moderate to severe myelofibrosis.",[106,108,109,529],"Myelofibrosis (MF)",{"date":468,"type":32},{"date":276,"type":21},{"date":116,"type":21},{"name":38,"class":39},{"id":535,"slug":536,"hasResults":12,"nctId":537,"briefTitle":538,"officialTitle":538,"acronym":539,"eligibilityCriteria":540,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":541,"enrollmentInfo":542,"targetDuration":4,"studyType":22,"phases":544,"briefSummary":545,"conditions":546,"keywords":548,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":550,"startDateStruct":551,"completionDateStruct":553,"leadSponsor":554,"locationsCount":90},"100618726","phase-2-prp-combined-with-botulinum-toxin-type-a-injection-for-the-treatment-of-androgenetic-alopecia-a-study-100618726","NCT07335367","PRP Combined With Botulinum Toxin Type A Injection for the Treatment of Androgenetic Alopecia: A Study","AGA","Inclusion Criteria:\n\n1. Patients who meet the diagnostic criteria for AGA, confirmed by medical history, clinical presentation, and trichoscopy, with a stage of Norwood-Hamilton III to V or Ludwig I to III.\n2. Patients provide informed consent and voluntarily participate in the study.\n3. A signed informed consent form is obtained.\n4. Age between 18 and 60 years, in good general health.\n5. No use of any medications for AGA treatment within the past 6 months.\n6. Absence of alopecia areata, local infection, or neuromuscular diseases.\n\nExclusion Criteria:\n\n1. Disease duration exceeding 5 years.\n2. Patients who do not meet the diagnostic criteria for AGA.\n3. Individuals with coagulation disorders.\n4. Patients with active skin diseases or other severe systemic illnesses.\n5. Patients with blood-borne infectious diseases such as Hepatitis A, Hepatitis B, HIV\u002FAIDS, or Syphilis.\n6. Use of any medications for hair loss treatment within the past 6 months.\n7. Other conditions deemed by the investigator as unsuitable for participation, including but not limited to unreliable patients, or those unable to undergo or comprehend the study assessments.","60 Years",{"count":543,"type":21},76,[102],"Research Purpose\n\nThe objective of this study is to determine the safety and efficacy of combined PRP and BTX-A injection therapy for Androgenetic Alopecia (AGA).\n\nStudy Content\n\nThis clinical trial is a randomized (1:1), multicenter, parallel-group, controlled study. AGA patients aged 18 to 60 years presenting to the participating centers will be recruited. After providing informed consent, eligible patients who meet the inclusion\u002Fexclusion criteria will be randomized in a 1:1 ratio, with separate randomization schedules for male and female patients, into either the experimental group (PRP combined with BTX-A injection) or the control group (PRP injection only). A total of 76 patients will be enrolled.\n\nControl Group: Subjects randomized to the control group will receive PRP injection therapy. The PRP will be administered intradermally (at a depth of approximately 1.5-2.5 mm, with injection points 1 cm apart) into the scalp area (defined as ≥12 cm from the lateral canthus and ≥9 cm from the top of the ear, encompassing the frontal, temporal, parietal, and occipital regions) at a dose of 0.1 ml\u002Fcm². The treatment regimen consists of monthly injections, 4 ml per session, for a total of 3 consecutive sessions.\n\nExperimental Group: Subjects randomized to the experimental group will receive injections using the same method and frequency as the control group. For the first session, the injection will consist of 100U of BTX-A reconstituted in 4 ml of PRP. The second and third sessions will be identical to those in the control group (PRP injection only).\n\nFollow-up Assessments: For all subjects, a safety evaluation will be conducted 14 days after the first treatment, along with scalp care guidance provided by the investigator. Subsequent safety and efficacy assessments will be performed at 1, 2, 3, and 6 months following the initial treatment.",[547],"Androgenetic Alopecia (AGA)",[549],"Platelet-Rich Plasma",{"date":440,"type":32},{"date":552,"type":32},"2026-01-09",{"date":88,"type":21},{"name":38,"class":39},{"id":556,"slug":557,"hasResults":12,"nctId":558,"briefTitle":559,"officialTitle":559,"acronym":4,"eligibilityCriteria":560,"healthyVolunteers":196,"sex":17,"minAge":18,"maxAge":197,"enrollmentInfo":561,"targetDuration":47,"studyType":177,"phases":4,"briefSummary":563,"conditions":564,"keywords":566,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":571,"startDateStruct":573,"completionDateStruct":575,"leadSponsor":577,"locationsCount":90},"100611420","the-role-and-regulatory-mechanism-of-germinal-center-immune-response-in-hepatitis-b-virus-infection-100611420","NCT07240350","The Role and Regulatory Mechanism of Germinal Center Immune Response in Hepatitis B Virus Infection","Inclusion Criteria:\n\n1. Male or female, patients with chronic hepatitis B and hepatitis B surface antigen negative patients with clinical diagnosis who need to undergo liver, spleen, tonsil or lymph node surgery.\n2. Before performing any research-related steps, the patient understood the research process, signed the informed consent, and complied with the research requirements.\n3. Patients diagnosed with chronic hepatitis B virus infection according to the \"Guidelines for the Prevention and Treatment of Chronic Hepatitis B(2019 Version)\" .\n\nExclusion Criteria:\n\n1. Those concomitant HCV, HIV infection, alcoholic fatty liver disease, non-alcoholic fatty liver disease, and autoimmune liver disease , etc. were excluded.\n2. Diseases of the immune system or coagulation system, such as hyperthyroidism, diabetes, thrombocytopenic purpura, etc., were excluded.\n3. Exclude serious underlying diseases that affect the immune status of the body.\n4. The investigator believes that there are other circumstances that are not suitable for inclusion.",{"count":562,"type":21},280,"The purpose of this observational study is to investigate the structure and composition of germinal centers in individuals with chronic HBV infection. The primary questions it aims to address are:\n\nWhat are the phenotypes, functions, and complexity of B cell clones of the immune cells within the germinal centers of chronic HBV-infected individuals? Do chronic HBV-infected individuals have ectopic germinal centers in the liver? This will be studied by collecting peripheral blood and discarded liver, lymph node, and tonsil tissues from chronic HBV patients undergoing lymph node surgery, hepatectomy, and tonsillectomy.",[565],"Hepatitis B Virus Infection",[567,568,569,570],"Germinal center","humoral immunity","immune response","hepatitis B virus infection",{"date":572,"type":32},"2026-04-16",{"date":574,"type":32},"2021-01-01",{"date":576,"type":21},"2027-02-12",{"name":38,"class":39},{"id":579,"slug":580,"hasResults":12,"nctId":581,"briefTitle":582,"officialTitle":582,"acronym":4,"eligibilityCriteria":583,"healthyVolunteers":196,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":584,"targetDuration":586,"studyType":177,"phases":4,"briefSummary":587,"conditions":588,"keywords":593,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":597,"startDateStruct":598,"completionDateStruct":600,"leadSponsor":601,"locationsCount":90},"100613358","single-cell-multiomics-and-spatiotemporal-omics-analyze-the-mechanism-of-liver-degenerative-disease-100613358","NCT07265544","Single-cell Multiomics and Spatiotemporal Omics Analyze the Mechanism of Liver Degenerative Disease","Inclusion Criteria:\n\n1. Voluntarily signed the informed consent form;\n2. No restrictions on age and gender;\n3. Patients diagnosed with hepatic hemangioma or focal nodular hyperplasia of the liver in accordance with the \"Guidelines for the Diagnosis and Treatment of Focal Liver Lesions (2014 Edition)\" and the \"Guidelines for the Diagnosis and Treatment of Hemangiomas and Vascular Malformations (2019 Edition)\";\n4. Patients with hepatic hemangioma, focal nodular hyperplasia of the liver, fatty liver, HBV infection, liver fibrosis, and cirrhosis who clinically require liver surgery or liver biopsy.\n\nExclusion Criteria:\n\n1. Individuals with concurrent infections such as HIV will be excluded.\n2. Patients with coagulation system disorders, such as hemophilia or idiopathic thrombocytopenic purpura, will not be included.\n3. Those with severe underlying diseases that affect the body's immune status will be excluded.\n4. Individuals whom the investigator deems unsuitable for participation in this study will be excluded.",{"count":585,"type":21},240,"7 Days","The purpose of this observational study is to employ single-cell multi-omics and spatial omics technologies to characterize the spatial and immune structures within the livers of patients with fatty liver, hepatic hemangioma, focal nodular hyperplasia, liver fibrosis, cirrhosis, and HBV infection. The primary questions it aims to address are:\n\nInvestigate the mechanisms of liver degenerative changes during the processes of liver aging, fatty liver, HBV infection, liver fibrosis, and cirrhosis.\n\nCharacterize the molecular features and cellular networks at different stages of liver degeneration and identify new targets and mechanisms for the cure of the aforementioned diseases.\n\nThe study will collect peripheral blood and discarded liver tissue from patients with hepatic hemangioma, fatty liver, HBV infection, liver fibrosis, and cirrhosis who are undergoing hepatectomy or liver biopsy.",[589,590,591,592],"Liver Neoplasm","HBV Infection","Non-alcoholic Fatty Liver Disease NAFLD","Liver Fibrosis",[594,595,596],"single-cell multi-omics","HBV infection","liver degenerative changes",{"date":440,"type":32},{"date":599,"type":32},"2023-03-01",{"date":576,"type":21},{"name":38,"class":39},""]